No Data
No Data
Birdman ETC [Stocks with interesting features seen from Volume changes]
Closing price and changes from the previous day Volume * <7063> Birdman 2,316,718,200 * <149A> Shinka 1,074,150,153,700 * <3238> Central General 4,791,138,800 * <1560> Bursa KLCI 5,180,301,068 * <9561> Glad Cube 89,126,375,200 * <9791> Biken Tech 1,012,653,1900 * <8707> Iwai Koss Corp 256,049,353,200 * <9658> Bizi Tai Show 269,314,162,800
Individual stock information.
Kei Pharma <4896.T> is under a stop-high buy order. Keio University School of Medicine, which conducts joint research with the company, announced new research findings on regenerative medicine targeting subacute spinal cord injuries, one of the candidates in the development pipeline for regenerative medicine, on the weekend of the 21st. In the clinical study of regenerative medicine using iPS cell-derived neural progenitor cells, improvements were observed in two out of four patients. Saifuse <4892.T> Tokyo Stock Exchange is utilizing Margin Trading.
Requio Pharmaceuticals, GDH and others.
<3133> Kaifan Birdman contracted with <7063> for business outsourcing <4169> Enechange recorded a subsidy income of 0.041 billion yen as non-operating income <4437> GDH increased Dividends, the end-of-term Dividends per share is 4.00 yen, up from 3.00 yen <4475> HENGGE established a joint venture (consolidated subsidiary) in the USA <4579> Raqualia Pharmaceuticals entered into a capital and business alliance with HK inno.N Corporation (South Korea) through a third-party allocation of new stock issuance (2.59 million 21.
Birdman: Half Year Report - Term 13 (2024/07/01 - 2025/06/30)
Birdman: Summary of financial results for the 2nd quarter (interim period) of the fiscal year ending 2025/6 [Japanese GAAP] (consolidated)
Birdman 1H Loss Y397.00M Vs Loss Y171.00M